Amerge Side Effects
Generic name: naratriptan
Note: This document contains side effect information about naratriptan. Some of the dosage forms listed on this page may not apply to the brand name Amerge.
Some side effects of Amerge may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to naratriptan: oral tablet
Along with its needed effects, naratriptan (the active ingredient contained in Amerge) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking naratriptan:More common
- Chest pain (severe)
- heaviness, tightness, or pressure in the chest, throat, or neck
- sensation of burning, warmth, heat, numbness, tightness, or tingling
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- Convulsions (seizures)
- irregular heartbeat
- slow heartbeat
Some side effects of naratriptan may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- bone pain
- change in taste sensation
- chills or fever
- difficulty with sleeping
- eye problems
- general feeling of discomfort or illness
- joint pain
- muscle or joint stiffness, tightness, or rigidity
- pounding heartbeat
- stomach discomfort or pain
- trembling or shaking of the hands or feet
- unusual tiredness or weakness
For Healthcare Professionals
Applies to naratriptan: oral tablet
Nervous system side effects have been reported in 7% of patients receiving 2.5 mg, 4% of patients receiving 1 mg, and 3% of patients receiving placebo. These effects included dizziness in 2% of patients receiving 2.5 mg and 1% of patients receiving 1 mg or placebo. These neurological adverse effects also include drowsiness in 2% of patients receiving 2.5 mg, 1% of patients receiving 1 mg, and <1% of patients receiving placebo. Malaise/fatigue have been reported in 2% of patients receiving either 2.5 or 1 mg, and 1% of patients receiving placebo.
Cerebral vascular accidents, including transient ischemic attack, subarachnoid hemorrhage, and cerebral infarction have been reported. Vertigo has been reported frequently. Tremors, disorders of cognitive function, sleep, and/or equilibrium have been reported infrequently. Compressed nerve syndromes, confusion, sedation, hyperesthesia, coordination disorders, paralysis of cranial nerves, decreased consciousness, dreams, altered sense of taste, neuralgia, neuritis, aphasia, hypoesthesia, motor retardation, muscle twitching and fasciculation, psychomotor restlessness, and convulsions have been reported rarely.
Atypical sensation has been reported in 4% of patients receiving 2.5 mg, 2% of patients receiving 1 mg, and 1% of patients receiving placebo. These sensations included paresthesias in 2% of patients receiving 2.5 mg, 1% of patients receiving 1 mg, and <1% of patients receiving placebo. Warm/cold temperature sensations have been reported frequently. A strange feeling and a burning/stinging sensation have been reported infrequently.
Gastrointestinal side effects have been reported in 7% of patients receiving 2.5 mg, 6% of patients receiving 1 mg, and 5% of patients receiving placebo. These effects included nausea in 5% of patients receiving 2.5 mg, and 4% in patients receiving 1 mg or placebo. Colonic ischemia with abdominal pain and bloody diarrhea has also been reported in patients using naratriptan (the active ingredient contained in Amerge) Hyposalivation has been reported frequently. Dyspeptic symptoms, diarrhea, gastrointestinal discomfort and pain, gastroenteritis, and constipation have been reported infrequently. Abnormal liver function tests, abnormal bilirubin levels, hemorrhoids, gastritis, esophagitis, salivary gland inflammation, oral itching and irritation, reflux, regurgitation, and gastric ulcers have been reported rarely.
While vomiting has been reported frequently, it occurred even more frequently in subjects receiving placebo than in patients receiving 2.5 mg.
Other side effects have included pain and pressure sensation which have been reported in 4% of patients receiving 2.5 mg, and 2 % of patients receiving 1 mg or placebo. Throat/neck symptoms have been reported in 2% of patients receiving 2.5 mg and 1% of patients receiving 1 mg or placebo. Pressure/tightness/heaviness sensations have been reported frequently. Drug-induced headache has also been reported.
Ear, nose, and throat infections have been reported frequently. Phonophobia, sinusitis, upper respiratory inflammation, and tinnitus have been reported infrequently. Allergic rhinitis, labyrinthitis, hearing difficulty, and hemorrhage of the ear, nose, and throat, have been reported rarely.
Chills and/or fever, edema and swelling have been reported infrequently. Spasms and mobility disorders have been reported rarely.
Cardiovascular side effects including palpitations, increased blood pressure, tachyarrhythmias, and abnormal ECG (PR prolongation, QTc prolongation, ST/T wave abnormalities, premature ventricular contractions, atrial flutter, or atrial fibrillation), peripheral vascular ischemia, and syncope have been reported infrequently. Bradycardia, varicosities, hypotension, and heart murmurs have been reported rarely. Angina and myocardial infarction have also been reported.
Endocrine side effects including thirst and polydipsia, dehydration, and fluid retention have been reported infrequently. Hyperlipidemia, hypercholesterolemia, hypothyroidism, hyperglycemia, glycosuria, ketonuria, and parathyroid neoplasm have been reported rarely.
Ocular side effects including photophobia have been reported frequently. Blurred vision has been reported infrequently. Eye pain and discomfort, sensation of eye pressure, eye hemorrhage, dry eyes, difficulty focusing, and scotoma have been reported rarely.
Hematologic side effects including increased white blood cells have been reported infrequently. Thrombocytopenia, quantitative red blood cell or hemoglobin defects, anemia, and purpura have been reported rarely.
Respiratory side effects including bronchitis, cough, and pneumonia have been reported infrequently. Tracheitis, asthma, pleuritis, and airway constriction and obstruction have been reported rarely. Dyspnea has also been reported.
Musculoskeletal side effects including muscle pain, arthralgia and articular rheumatism, muscle cramps and spasms, joint and muscle stiffness, tightness, and rigidity have been reported infrequently. Bone and skeletal pain have been reported rarely.
Hypersensitivity side effects have been reported including anaphylaxis/anaphylactoid reactions, in some cases severe (e.g., circulatory collapse). Allergies and allergic reactions have been reported infrequently.
Psychiatric side effects including anxiety, depressive disorders, and detachment have been reported infrequently. Aggression and hostility, agitation, hallucinations, panic, and hyperactivity have been reported rarely.
Genitourinary side effects including bladder inflammation, polyuria, and diuresis have been reported infrequently. Urinary tract hemorrhage, urinary urgency, pyelitis, urinary incontinence, lumps of the female reproductive tract, inflammation of the breast, vagina, and/or fallopian tube, breast discharge, endometrium disorders, decreased libido, and breast lumps have been reported rarely.
Dermatologic side effects including sweating, skin rashes, pruritus, and urticaria have been reported infrequently. Skin erythema, dermatitis and dermatosis, hair loss and alopecia, pruritic skin rashes, acne and folliculitis, allergic skin reactions, macular skin/rashes, skin photosensitivity, photodermatitis, skin flakiness, and dry skin have been reported rarely.
More Amerge resources
- Amerge Prescribing Information (FDA)
- Amerge MedFacts Consumer Leaflet (Wolters Kluwer)
- Amerge Concise Consumer Information (Cerner Multum)
- Amerge Advanced Consumer (Micromedex) - Includes Dosage Information
- Amerge Monograph (AHFS DI)
- Naratriptan Prescribing Information (FDA)
- Naratriptan Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.